It is estimated that between 13 and 17% of ICCAs harbor genomic alterations in the FGFR2 gene and that most of these alterations (i.e. fusions) predict tumor sensitivity to anti-FGFR2 tyrosine kinase inhibitors17,18. This evidence concerns the gene FGFR2 and neoplasm.